Manufacturing News of Note–GlaxoSmithKline strikes a deal for manufacturing T cells

Inn this week's news of note stories about GlaxoSmithKline, Samsung and Recipharm. (Pixabay)

> GlaxoSmithKline has struck a deal with Hitachi Chemical Advanced Therapeutics Solutions to manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US, Canadian and European trials. Release

> Recipharm has completed its $60 million buyout of Sanofi’s contract inhalation drug business and plant in the U.K. Release

> South Korean CDMO Samsung BioLogics has started production of its Plant 3, what it is referring to as the world’s largest single bio manufacturing plant. Release

Suggested Articles

Boehringer Ingelheim intends to make a significant investment in its three manufacturing sites in Mexico in the next three years.

Dendreon has signaled faith in its struggling prostate drug Provenge by signing a 10-year lease extension for its California manufacturing facility.

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.